ArticleBMC neurology2025
The metabolic crossroads: glycolysis in cancer and neurodegeneration.
Article in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEmerging epidemiological data reveal a compelling inverse relationship between cancer and neurodegenerative diseases, including Parkinson's disease (PD) and Alzheimer's disease (AD). The biological mechanisms underlying this paradox remain unclear. The aim of this study was to identify shared metabolic pathways that may mediate this inverse association.
methodsWe integrated single-cell and bulk RNA sequencing data from TCGA and GEO databases to examine metabolic alterations in colon adenocarcinoma (COAD) and PD. Furthermore, we validated the expression of the critical gene in human tissue samples using immunohistochemistry and corroborated its functional roles through in vitro experimental assays.
resultsDivergent regulation of glycolysis was observed between COAD and PD. A key finding was the upregulation of acetyl-CoA acyltransferase 2 (ACAA2) in PD and, more markedly, in AD, contrasting with its frequent downregulation in cancers. Functionally, ACAA2 overexpression has been demonstrated to inhibit glycolysis and inflammation in colorectal cancer and neurological models.
conclusionsOur findings identify glycolysis as a shared but oppositely regulated pathway linking cancer and neurodegeneration. ACAA2 may serve as a molecular mediator of this metabolic divergence, offering new insights into disease crosstalk and potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.